OUR CLINICAL PROGRAMS
NON-HEALING WOUNDS AND ONCOLOGY
AUP-16: PHASE 1 CLINICAL STUDY IN DIABETIC FOOT ULCERS
In June 2022, we successfully completed the Phase 1 study in non-healing Diabetic Foot Ulcer patients with our lead product AUP-16. While patient observation continues, collected data will be processed and consolidated for publication.
Aurealis Therapeutics technology platform works in real life: non-healing diabetic wounds heal. Clinical results: 83% of patients reached complete healing.
83% of patients reached complete healing
no recurrEnce during 3 months follow-up
AUP-16: PHASE 2 CLINICAL STUDIES IN DIABETIC FOOT ULCER, VENOUS ULCER AND PRESSURE ULCER
We are about to start our Phase 2 clinical study in Diabetic Foot Ulcers. Clinical centers are being recruited in Italy, Germany and Poland.
Phase 2 Venous Leg Ulcer and Pressure Ulcer will follow.
AUP-55: PRE-CLINICAL STUDY IN MOUSE OVARIAN CANCER
Aurealis AUP platform shows efficacy in oncology, where we have excellent pre-clinical data. This is an example in advanced ovarian cancer.
Tumor implantation took place at day 0. Treatment started at day 14, After 30 days, all control animals have died from the tumor. But after 80 days, more than 90% of the animals treated with AUP-55 or AUP-65 are still alive.